ストックスクリーナーアプリを入手
5.16
3.19%
-0.17
前日終値:
$5.33
開ける：
$5.5
24時間の取引高:
505.11K
Relative Volume:
0.45
時価総額：
$437.02M
収益：
$73.48M
当期純損益:
$-108.30M
株価収益率:
-2.2933
EPS:
-2.25
ネットキャッシュフロー:
$-67.17M
1週間 パフォーマンス:
-3.73%
1か月 パフォーマンス:
-19.50%
6か月 パフォーマンス:
+61.25%
1年 パフォーマンス:
+316.13%
1日の値動き範囲:
$5.16
$5.62
1週間の範囲:
$4.815
$5.62
52週間の値動き範囲:
$1.12
$7.20
Personalis Inc Stock (PSNL) Company Profile
PSNL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
5.16 | 437.02M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
572.71 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.01 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
147.64 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
209.96 | 38.11B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
460.56 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-02-06 | アップグレード | Needham | Hold → Buy |
| 2022-01-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-11-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-03 | ダウングレード | Needham | Buy → Hold |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-09-20 | 繰り返されました | Needham | Buy |
| 2021-05-06 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-01-28 | 開始されました | Truist | Buy |
| 2021-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-12 | 繰り返されました | Needham | Buy |
| 2020-11-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-10-19 | 開始されました | Citigroup | Buy |
| 2020-10-08 | 開始されました | BTIG Research | Buy |
| 2020-08-27 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-18 | 開始されました | Needham | Buy |
| 2019-09-26 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-07-15 | 開始されました | BofA/Merrill | Neutral |
| 2019-07-15 | 開始されました | Cowen | Outperform |
| 2019-07-15 | 開始されました | Morgan Stanley | Overweight |
| 2019-07-15 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Personalis Inc (PSNL) 最新ニュース
Wall Street analysts’ outlook for Personalis Inc (PSNL) - SETE News
Should You Expect A Quick Recovery From Personalis Inc (NASDAQ: PSNL) After -35.08% Decline From High? - Marketing Sentinel
Personalis Inc (PSNL) is a good investment, but the stock may be overvalued - US Post News
Needham analysts upgrades a Buy rating for Personalis Inc (PSNL) - Knox Daily
Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny - Simply Wall St
FY2024 EPS Estimates for Personalis Lowered by HC Wainwright - MarketBeat
Analysts Issue Forecasts for Personalis FY2029 Earnings - MarketBeat
FY2024 EPS Estimates for Personalis Reduced by HC Wainwright - Defense World
Personalis price target lowered to $8 from $11 at H.C. Wainwright - MSN
Brokers Set Expectations for Personalis FY2029 Earnings - Defense World
Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference - Marketscreener.com
Precision Oncology Leader Personalis Takes Center Stage at Major Healthcare Summit - StockTitan
Personalis stock price target cut to $8 by H.C. Wainwright - MSN
Personalis (NASDAQ:PSNL) Given New $8.00 Price Target at HC Wainwright - Defense World
Personalis Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
HC Wainwright Cuts Personalis (NASDAQ:PSNL) Price Target to $8.00 - MarketBeat
Personalis (PSNL) Upgraded to Buy: Here's Why - Yahoo Finance
Personalis, Inc. (NASDAQ:PSNL) Stock Position Increased by Barclays PLC - Defense World
Researchers find ctDNA test predicts lung cancer outcomes in study - Yahoo Finance
New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer - sharewise
Catherine Wood's Strategic Acquisition of Personalis Inc Shares - GuruFocus.com
Personalis Lung Cancer Test Shows 100% Detection Rate in Breakthrough Study - StockTitan
Personalis (NASDAQ:PSNL) Stock Price Expected to Rise, Lake Street Capital Analyst Says - Defense World
Personalis stock target lifted, retains buy on impressive performance By Investing.com - Investing.com Canada
Personalis (NASDAQ:PSNL) Price Target Raised to $9.00 - MarketBeat
Personalis stock target lifted, retains buy on impressive performance - Investing.com India
Personalis (NASDAQ:PSNL) Earns Buy Rating from HC Wainwright - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Personalis (NASDAQ:PSNL) - MarketBeat
Geode Capital Management LLC Buys 83,068 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue - The Bakersfield Californian
Personalis Beats 2024 Revenue Guidance with 15% Growth, Secures Moderna Partnership - StockTitan
Barclays PLC Buys 20,444 Shares of Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Stake Raised by State Street Corp - Defense World
Jane Street Group LLC Increases Stock Position in Personalis, Inc. (NASDAQ:PSNL) - Defense World
Personalis, Inc. (NASDAQ:PSNL) Stock Position Reduced by Stifel Financial Corp - Defense World
Personalis, Inc. Amends Sales Agreement with Piper Sandler & Co. and BTIG - Defense World
The 16% return this week takes Personalis' (NASDAQ:PSNL) shareholders one-year gains to 159% - Yahoo Finance
Grail (NASDAQ:GRAL) & Personalis (NASDAQ:PSNL) Financial Contrast - Defense World
Local vaccine biotech secures $50 million Merck investment - The Business Journals
Personalis price target raised to $8 from $7 at BTIG - Yahoo Finance
Personalis Announces Investment Agreement with Merck in Latest 8-K Filing - Defense World
Personalis Inc (PSNL) 財務データ
収益
当期純利益
現金流量
EPS
1.51%
大文字化:
|
ボリューム (24 時間):